Abstract: The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.

Abstract: The present invention relates to a recombinant antigen and an isolated polynucleotide of porcine reproductive and respiratory syndrome virus (PRRSV), a composition including the same and a method of making the same. The recombinant antigen is a chimeric protein of PRRSV dual structural proteins and T-cell epitope. The polynucleotide encodes an amino acid sequence of the recombinant antigen. The recombinant protein expressed by the polynucleotide in an eukaryotic expression system can be beneficial for mass production and purification. An immunogenic composition including the recombinant antigen can promote pro-inflammatory M1-phenotype polarization of porcine alveolar macrophages (PAMs), reduce receptor CD163 expression that is mediated for viral entry and activate T helper (Th1) immune responses, thereby being applied to a vaccine composition against PRRSV.

Abstract: The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.

Abstract: The present invention relates to an in vitro immune synapse system and a method of in vitro evaluating immune response using the same. The in vitro immune synapse system includes antigen-presenting cells (APCs) and at least one cell type of several specific T cell subtypes isolated from peripheral blood mononuclear cells (PBMCs), all of which is from a same individual of pigs. When a test sample is co-cultured in the in vitro immune synapse system for a given period, it can be determined that the test sample is immunogenic, immunostimulatory or not according to the immunization-related changes of these cells, thereby potentially replacing some kinds of animal experimentation.

Abstract: The present invention relates to a nucleic acid-based adjuvant and a porcine vaccine composition including the same. The nucleic acid-based adjuvant, which is a nucleic acid fragment consisting of a sequence listing as SEQ ID NO: 1, can be used as the nucleic acid-based adjuvant of a vaccine composition, thereby elevating the protective ability of the porcine vaccine composition.

Abstract: The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (PRRSV). A recombinant fusion antigen gene, which encodes glycoprotein GP5 with truncated N?-terminal decoy epitope, a linker sequence and membrane protein M, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein. The recombinant fusion antigen protein can be applied in a subunit vaccine composition, for providing vaccinated animals with better protection ability without the risks of virulent spread and virulent recovery.

Abstract: The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (PRRSV). A recombinant fusion antigen gene, which encodes glycoprotein GP5 with truncated N?-terminal decoy epitope, a linker sequence and membrane protein M, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein. The recombinant fusion antigen protein can be applied in a subunit vaccine composition, for providing vaccinated animals with better protection ability without the risks of virulent spread and virulent recovery.

Abstract: A Chinese herbal aqueous extract having anti-anxiety activities and a method of in vitro evaluating the same are disclosed. Neural cells and/or glial cells are cultured in a medium containing the Chinese herbal aqueous extract, and then subjected to an electric pulse treatment to form epileptic cells. The epileptic cells are applied on evaluation of at least one criterion of anti-anxiety activities of the Chinese herbal aqueous extract.

Abstract: A Chinese herbal aqueous extract having anti-anxiety activities and a method of in vitro evaluating the same are disclosed. Neural cells and/or glial cells are cultured in a medium containing the Chinese herbal aqueous extract, and then subjected to an electric pulse treatment to form epileptic cells. The epileptic cells are applied on evaluation of at least one criterion of anti-anxiety activities of the Chinese herbal aqueous extract.

Abstract: An active substance of medication or health product for hyperlipidemia and hypercholesterolemia comprises djulis, and which can effectively inhibit the absorption of cholesterol, advance the metabolism of cholesterol, promote the anti-oxidation and decrease the accumulation of oxidized low-density lipoprotein-cholesterol in vessel walls of organisms.

Abstract: A Chinese herbal aqueous extract having anti-anxiety activities and a method of in vitro evaluating the same are disclosed. Neural cells and/or glial cells are cultured in a medium containing the Chinese herbal aqueous extract, and then subjected to an electric pulse treatment to form epileptic cells. The epileptic cells are applied on evaluation of at least one criterion of anti-anxiety activities of the Chinese herbal aqueous extract.

Abstract: An active substance of medication or health product for hyperlipidemia and hypercholesterolemia comprises djulis, and which can effectively inhibit the absorption of cholesterol, advance the metabolism of cholesterol, promote the anti-oxidation and decrease the accumulation of oxidized low-density lipoprotein-cholesterol in vessel walls of organisms.

Abstract: The present invention provides a method for detecting a beta-glucan having immunomodulatory activity in a human cell, which uses a test cell line that stably expresses human dectin-1 molecule on the cell surface and does not express other glucan receptors and a specific amount of a marker beta-glucan that specifically binds to human dectin-1 molecule for detection.

Abstract: A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a sequence of SEQ ID NO: 2. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.

Abstract: A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a plurality of TCG tandem repeats at a 5?end, a poly-G structure at a 3? end, and at least one unmethylated CpG motif with avian specific flanking sequences at two ends thereof between the 5? end and the 3? end. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.

Abstract: The present invention provides for a method of preparing a nutraceutical formulation comprising the step of solvent extraction from the root of Zingiber zerumbet Sm, and the use of this formulation to regulate the immune system, and more specifically to prevent or to treat an allergic disorder.

Abstract: The present invention provides a method for detecting a beta-glucan having immunomodulatory activity in a human cell, which uses a test cell line that stably expresses human dectin-1 molecule on the cell surface and does not express other glucan receptors and a specific amount of a marker beta-glucan that specifically binds to human dectin-1 molecule for detection.

Abstract: The present invention provides for a method of preparing a nutraceutical formulation comprising the step of solvent extraction from the root of Zingiber zerumbet Sm, and the use of this formulation to regulate the immune system, and more specifically to prevent or to treat an allergic disorder.